GLP-1 Drugs in 2026: What They Do, Who They're For, and What the Research Says

What They Are

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — were originally developed for type 2 diabetes. The weight loss effects were discovered somewhat accidentally, and since 2021, weight management has become their primary use in millions of people worldwide.

They work by mimicking a hormone your gut releases after eating. The main effects: slowed gastric emptying (food leaves your stomach more slowly, keeping you full longer), reduced appetite signaling in the brain, and improved insulin regulation. It's more than just "hunger suppression" — these drugs appear to change how the brain responds to food cues and the reward from eating.

What the Trials Actually Show

The numbers are legitimate. The STEP trials showed semaglutide (Wegovy dose) producing an average 15% body weight reduction over 68 weeks. Tirzepatide (Zepbound) showed 20-22% in the SURMOUNT trials. To put that in context: that's 15-22kg for a 100kg person on average. These are the most effective pharmaceutical weight interventions ever studied.

Cardiovascular outcomes are also real. A 2023 trial (SELECT) showed semaglutide reduced major cardiovascular events by 20% in people without diabetes who were overweight. The FDA has since approved it for cardiovascular risk reduction specifically.

The Side Effects That Matter

Nausea affects roughly 44% of users, mostly in the first 4-8 weeks as the dose escalates. For most people this resolves. Vomiting occurs in about 25%. These are the main reasons people stop — not safety concerns, just discomfort.

Muscle loss is a more serious concern. Studies show 25-40% of weight lost on GLP-1 drugs is lean mass rather than fat. That's higher than typical caloric restriction. Resistance training and adequate protein intake (1.6-2g per kg of body weight) significantly reduce this. The drugs work better when combined with exercise for this reason.

The rebound issue is real. Most studies show that when people stop the medication, they regain roughly two-thirds of the lost weight within two years unless they've made significant lifestyle changes during treatment. These drugs don't cure obesity — they manage it, the way blood pressure medication manages hypertension.

Who They're Actually For

Clinical guidelines are consistent: BMI 30+ or BMI 27+ with a weight-related condition (type 2 diabetes, hypertension, sleep apnoea, cardiovascular disease). They're not approved or appropriate for people trying to lose 5-10kg for aesthetic reasons, though this doesn't stop off-label use.

Cost and Access in 2026

Prices have come down 30-40% from 2023 peaks as competition increased and supply stabilised. In Europe, a monthly dose runs €120-200 depending on country and whether it's covered by insurance. Oral semaglutide (Rybelsus) and oral tirzepatide are now commercially available, making adherence easier for people averse to injections. Generic versions are entering markets in some jurisdictions.